Astellas Pharma Inc Value Stock - Dividend - Research Selection
Fundamental data and company key figures of the share
|Annual reports in|
|Net operating cash flow|
|Free cash flow|
|Liabilities & Shareholders equity|
|Diluted shares outstanding|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Raw Data Source|
Description of the company
XTANDI (Prostate cancer treatment)
XTANDI is a treatment that decreases cell growth and induces apoptosis by inhibiting multiple steps in the androgen receptor signaling pathway, an important pathway in the growth of prostate cancer. XTANDI was first launched in 2012 with an indication for the treatment patients with metastatic castration-resistant prostate cancer (CRPC) whose disease has progressed on or after chemotherapy. Subsequently, it has also been approved for metastatic chemo-naïve CRPC patients. XTANDI is sold in approximately 70 countries/areas.
Eligard (Prostate cancer treatment)
Eligard is a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of prostate cancer that is marketed by Astellas in approximately 50 countries throughout the EMEA and Asia & Oceania regions.
Betanis / Myrbetriq / BETMIGA (OAB treatment)
Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Mirabegron is the only OAB treatment option in its class that targets the β3 pathway. Mirabegron is sold in approximately 50 countries worldwide under the brand name of Betanis in Japan, Myrbetriq in the U.S. and Canada, Myrbetric in Latin America, and BETMIGA in EU, MENASA, Russia/CIS, and Asia & Oceania.
Vesicare (OAB treatment)
Solifenacin is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin binds to certain natural body proteins (receptors) which help the bladder muscle to contract. This can help control the symptoms of frequent urges and leaks. Solifenacin is now marketed in approximately 80 countries worldwide.
Harnal / Omnic (Treatment for functional symptoms associated with benign prostatic hyperplasia (BPH))
Tamsulosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Tamsulosin is an α1 blocking agent with great selectivity for prostatic and urethral smooth muscle. It is marketed in approximately 100 countries worldwide.
VESOMNI is a modified release tablet of combination 6 mg solifenacin and 0.4 mg tamsulosin. VESOMNI is indicated for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy. VESOMNI is marketing in approximately 20 countries worldwide.
Prograf and Advagraf / Graceptor / ASTAGRAF XL / Prograf XL (Immunosuppressant)
This drug is an immunosuppressant used to suppress organ transplant rejection. It is sold in approximately 100 countries and regions and has made a significant global contribution in the field of transplantation.
Funguard / MYCAMINE (Candin-type antifungal agent)
This drug is a candin-type antifungal agent used for the treatment of fungal infections.
It operates by inhibiting synthesis of the fungus cell wall. It is marketed in about 60 countries around the world.